Breaking News Instant updates and real-time market news.

CRSP

Crispr Therapeutics

$17.07

0.36 (2.15%)

20:43
07/13/17
07/13
20:43
07/13/17
20:43

CRISPR Therapeutics initiated with a Hold at SunTrust

SunTrust analyst Peter Larson initiated CRISPR Therapeutics with a Hold and a $16 price target.

CRSP Crispr Therapeutics
$17.07

0.36 (2.15%)

03/28/17
CHDN
03/28/17
INITIATION
Target $23.5
CHDN
Buy
CRISPR Therapeutics initiated with a Buy at Chardan
Chardan analyst Madhu Kumar initiated CRISPR Therapeutics with a Buy and a $23.50 price target saying upside from clinical leadership in CRISPR therapy offsets any potential downside from its IP exposure.
02/16/17
PIPR
02/16/17
NO CHANGE
Target $21
PIPR
Overweight
Piper's Schimmer calls CRISPR selloff 'major overreaction'
Piper Jaffray analyst Joshua Schimmer views yesterday's selloff in shares of CRISPR Therapeutics (CRSP) as a "major overreaction." The stock closed yesterday down 8%, or $1.36, to $15.90 after the patent office did not allow the patent interference with UC Berkeley versus Broad Institute over a Crispr/Cas-9 patent. Now that it's deemed patentable, CRISPR will move forward to get its own claims issued and likely move towards a second interference, Schimmer tells investors in a research note. CRISPER and Intellia Therapeutics (NTLA) are essentially litigation partners against the Broad, and now have the chance to win by knocking out Editas Medicine's (EDIT) single-guide tracr patent or by showing it was the first to invent and reduce to practice the application in eukaryotes, the analyst contends. Schimmer says he can't understand why Editas' valuation is higher than CRISPR's. He believes it should be the opposite. The analyst keeps an Overweight rating on CRISPR with a $21 price target.
02/15/17
JEFF
02/15/17
NO CHANGE
JEFF
Patent ruling best case for Editas Medicine, says Jefferies
Jefferies analyst Gena Wang views the United States Patent and Trademark Office's judgment of "no interference-in-fact" for the CRISPR/Cas9 interference motion phase as the "best case" for Editas Medicine (EDIT), Broad Institute's licensee. The analyst sees three choices for The University of California, which has CRISPR Therapeutics (CRSP) and Intellia Therapeutics (NTLA) as licensees: Appeal, seek second interference, or discuss a settlement. Wang sees cross-licensing as the likely eventual path taken by both parties. CRISPR and Intellia could license from Editas the use of CRISPR in eukaryotic cells, while Editas could license from the two companies the use of single guide and tracrRNA, the analyst tells investors in a research note. She believes a royalty could be in the mid-single-digit range. Shares of Editas are up 33% to $24.99 in afternoon while CRISPR is down 13% to $15.05 and Intellia is down 11% to $12.26.
11/15/16
SBSH
11/15/16
INITIATION
Target $19
SBSH
Neutral
CRISPR Therapeutics initiated with a Neutral at Citi
Citi analyst Yigal Nochomovitz started CRISPR Therapeutics with a Neutral rating and $19 price target. The risk/reward is balanced with the stock up 25% since the initial public offering, Nochomovitz tells investors in a research note. The analyst sees "no clear winner" in the gene editing patent debate.

TODAY'S FREE FLY STORIES

GPN

Global Payments

$117.51

-0.24 (-0.20%)

05:09
06/18/18
06/18
05:09
06/18/18
05:09
Downgrade
Global Payments rating change  »

Global Payments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVOP

EVO Payments

$22.98

0.95 (4.31%)

05:05
06/18/18
06/18
05:05
06/18/18
05:05
Initiation
EVO Payments initiated  »

EVO Payments initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CB

Chubb

$130.91

0.81 (0.62%)

05:04
06/18/18
06/18
05:04
06/18/18
05:04
Downgrade
Chubb rating change  »

Chubb downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LDOS

Leidos

$60.17

-0.585 (-0.96%)

05:02
06/18/18
06/18
05:02
06/18/18
05:02
Downgrade
Leidos rating change  »

Leidos downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDFN

Redfin

$24.00

-0.64 (-2.60%)

, ZG

Zillow

$65.24

0.45 (0.69%)

05:00
06/18/18
06/18
05:00
06/18/18
05:00
Downgrade
Redfin, Zillow rating change  »

Redfin downgraded to Sell…

RDFN

Redfin

$24.00

-0.64 (-2.60%)

ZG

Zillow

$65.24

0.45 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZG

Zillow

$65.24

0.45 (0.69%)

04:58
06/18/18
06/18
04:58
06/18/18
04:58
Downgrade
Zillow rating change  »

Zillow downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVRG

Evergy

$52.75

0.8 (1.54%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
Evergy management to meet with Wolfe Research »

Wolfe Utilities Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

MDT

Medtronic

$86.78

0.2 (0.23%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
Medtronic management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

UPLD

Upland Software

$35.30

0.04 (0.11%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
Upland Software management to meet with Craig Hallum »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 26

    Jun

NUVA

NuVasive

$55.27

0.49 (0.89%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
NuVasive management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 19

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

WMGI

Wright Medical

$25.83

-0.26 (-1.00%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
Wright Medical management to meet with Leerink »

Meeting to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

BR

Broadridge

$114.93

0.06 (0.05%)

, RRC

Range Resources

$15.96

-0.19 (-1.18%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Hot Stocks
Breaking Hot Stocks news story on Broadridge, Range Resources »

Broadridge to replace…

BR

Broadridge

$114.93

0.06 (0.05%)

RRC

Range Resources

$15.96

-0.19 (-1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

04:55
06/18/18
06/18
04:55
06/18/18
04:55
General news
Breaking General news story  »

Atlanta Federal Reserve…

04:55
06/18/18
06/18
04:55
06/18/18
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

VRX

Valeant

$26.86

0.06 (0.22%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
Breaking Conference/Events news story on Valeant »

FDA PDUFA Date for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 27

    Aug

HFC

HollyFrontier

$72.38

-0.61 (-0.84%)

, AYI

Acuity Brands

$122.14

1.465 (1.21%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Hot Stocks
Breaking Hot Stocks news story on HollyFrontier, Acuity Brands »

HollyFrontier to replace…

HFC

HollyFrontier

$72.38

-0.61 (-0.84%)

AYI

Acuity Brands

$122.14

1.465 (1.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEL

TE Connectivity

$98.98

-0.33 (-0.33%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
TE Connectivity management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 20

    Jun

ETSY

Etsy

$42.53

0.94 (2.26%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
Etsy management to meet with Loop Capital »

Field trip to company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
Federal Reserve Bank of Atlanta president speaks at a meeting »

Atlanta Federal Reserve…

PTC

PTC

$94.87

-0.46 (-0.48%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
PTC to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

WFC

Wells Fargo

$54.99

0.23 (0.42%)

, MS

Morgan Stanley

$51.17

-0.12 (-0.23%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
Federal Reserve Bank of New York to hold a conference »

Reforming Culture &…

WFC

Wells Fargo

$54.99

0.23 (0.42%)

MS

Morgan Stanley

$51.17

-0.12 (-0.23%)

BAC

Bank of America

$29.27

-0.24 (-0.81%)

C

Citi

$66.34

0.18 (0.27%)

WBK

Westpac Banking

$20.67

0.125 (0.61%)

GS

Goldman Sachs

$232.00

-1.695 (-0.73%)

BCS

Barclays

$10.59

-0.225 (-2.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 19

    Jun

  • 21

    Jun

  • 22

    Jun

  • 13

    Jul

  • 10

    Sep

  • 14

    Jan

  • 12

    Apr

  • 15

    Apr

  • 13

    Jul

  • 16

    Jul

  • 15

    Oct

  • 15

    Oct

OAS

Oasis Petroleum

$12.01

-0.63 (-4.98%)

, OMP

Oasis Midstream Partners

$17.29

-1.02 (-5.57%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
JPMorgan to hold a conference »

3rd Annual Energy Equity…

OAS

Oasis Petroleum

$12.01

-0.63 (-4.98%)

OMP

Oasis Midstream Partners

$17.29

-1.02 (-5.57%)

SRCE

1st Source

$55.36

0.13 (0.24%)

LGCY

Legacy Reserves

$6.07

-0.03 (-0.49%)

EVA

Enviva

$29.35

0.15 (0.51%)

CRC

California Resources

$35.03

-2.57 (-6.84%)

INSM

Insmed

$26.74

-1.5 (-5.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 28

    Sep

PFE

Pfizer

$36.36

0.19 (0.53%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
Pfizer management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

MIK

Michaels

$18.00

-0.86 (-4.56%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
Michaels management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

CHE

Chemed

$324.80

-1.67 (-0.51%)

, ENDP

Endo

$8.87

-0.045 (-0.50%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Hot Stocks
Breaking Hot Stocks news story on Chemed, Endo »

Chemed to replace Endo in…

CHE

Chemed

$324.80

-1.67 (-0.51%)

ENDP

Endo

$8.87

-0.045 (-0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.